Regulations
The key regulatory requirements for overseas manufacturers' APAC medical device registration in China, Japan, and South Korea.
China Medical Device Registration (NMPA): Requires foreign manufacturers to appoint a domestic agent and generally possess a valid home-country marketing certificate (e.g., FDA/CE). Registration is risk based filing for Class I, formal registration for Class II/III. All documentation must be submitted in Chinese, and acceleration tracks are available for innovative or priority products.
Japan Medical Device Registration (MHLW/PMDA): Requires the mandatory appointment of a licensed local Marketing Authorization Holder (MAH) who assumes legal responsibility.Pathways based on risk classification (I-IV), including notification (Class I), third-party Certification standard Class II/III, or formal MHLW Approval Class IV and novel devices. Overseas facilities require Foreign Manufacturer Registration and periodic QMS audits not less than three years.
South Korea Medical Device Registration (MFDS/NIFDS): Requires a licensed local importer who must obtain an Import Business License concurrently with the initial product license. Class I and standard Class II devices use rapid certification/notification routes, while Class III/IV and complex devices require direct NIFDS approval, with standard technical reviews taking 55-70 days. Separate acts govern Digital Medical Products and In Vitro Diagnostic Medical Devices.
China Medical Device Registration
To register an imported medical device or in-vitro diagnostic (IVD) reagent, you must provide a valid marketing certificate like a US FDA approval or a European CE mark issued by the competent authority of your home country or physical manufacturing site location. If your product is not classified as a medical device in your origin country, you are not exempt; you must provide proof of explicit permission for marketing it as a non-medical device there. The single exception to this country-of-origin certificate rule applies to products formally recognized under China’s innovative medical device pathways.
Classification Pathways for China Medical Device Registration
The regulatory framework manages medical devices and IVD reagents through a risk-based dual system of filing and registration centralized at the national level. Class I medical devices and IVDs are subject to product filing management, which requires the filing entity to submit necessary documentation directly to the National Medical Products Administration (NMPA) higher-risk Class II and Class III medical devices and IVD reagents must undergo product registration. According to the provisions, the Center for Medical Device Evaluation of NMPA (CMDE) conducts the formal technical evaluations for these imported Class II and Class III initial registrations, changes, and renewals before an official China medical device registration certificate can be issued. Products originating from Hong Kong SAR, Macao, and Chinese Taipei are legally bound to these exact import registration and filing pathways.
Mandatory Dossier and Technical Requirements
All application documentation must be submitted in Chinese via an online application system. When technical dossiers are translated from a foreign language, the original-language documents must be provided simultaneously for comparison, and legal permissions must be included for any referenced unpublished literature. According to Article 52 for medical devices and Article 51 for IVD reagents, the mandatory registration dossier must feature product risk analysis data, product technical requirements (PTR), an official test report, clinical evaluation materials, instructions for use (IFU), sample labels, and quality management system (QMS) documentation related to R&D and manufacturing. For Class III IVD reagents, the PTR must specific contain a mandatory annex clarifying the technical requirements for the main raw materials and manufacturing processes.
Non-Clinical Testing and R&D Specifications
Device research and development must follow risk management principles, executing non-clinical studies across physical, chemical, electrical, biological, software, sterilization, animal, and stability domains. Manufacturers must compile a PTR containing objective safety indicators and test methods, as the final distributed device must harmonize to this specification. Prior to clinical trials or registration, testing must be performed according to the PTR using GMP-conforming samples that fully represent the final device. Overseas manufacturers may submit either a self-test report from their own facility or a report from an entrusted third-party testing institution. However, Class III IVD reagents carry a mandate requiring test reports sampled from three separate batches, and national reference standards must be used if applicable.
Clinical Evaluation and Trial Frameworks under China Medical Device Regulations
Applicants must conduct a scientific clinical evaluation unless the product qualifies for an exemption under a formal catalogue adjusted by the NMPA. Exemptions apply if a device has a completely definite mechanism, finalized design, established manufacturing history, and a predicate device in clinical use for years without serious adverse events, or if safety can be proven through non-clinical or methodological comparisons. If non-exempt, safety must be proven via comparison dossiers against a predicate device or by conducting local clinical trials to secure your China medical device registration. Trials must comply with Good Clinical Practice (GCP) within a qualified Chinese institution after filing the project with the local provincial drug regulatory department. High-risk Class III medical device trials require prior NMPA approval, are restricted to Tertiary A medical institutions, and the approval expires if no subject signs the informed consent form within three years. Notably, standalone calibrators and control materials do not require clinical evaluation documents under current China medical device regulations.
Manufacturing Compliance and Quality Management System (QMS)
Manufacturing setups require highly traceable technical dossiers spanning personnel records, academic degrees of management heads, cleanroom environmental controls, equipment inventories, manufacturing flow charts, and corporate quality manuals. During technical evaluation, the CMDE may notify the Center for Food and Drug Inspection (CFDI) to execute a QMS inspection at the manufacturing site, which focuses heavily on design, production records, and raw data verification if self-test reports are used. To maintain ongoing compliance, the domestic agent must submit an annual QMS self-inspection report to their local provincial drug regulatory department before March 31 of each subsequent year. Additionally, manufacturers must fully implement Unique Device Identification (UDI) protocols for supply-chain traceability, and lines suspended for over a year must undergo verification protocols and reports.
Acceleration Tracks
Three specialized administrative tracks are available to accelerate market access for overseas manufacturers meeting technical benchmarks.The Innovative Product Procedures track applies if the applicant legally owns a core technology invention patent authorized in China within the last 5 years, the primary mechanism is the first of its kind nationally, and the technology reaches international advanced levels with significant clinical value. This track opens a dedicated communication channel with the CMDE to discuss protocols before formal acceptance. The Priority Registration Procedures track applies to devices diagnosing or treating rare diseases, malignant tumors, pediatric or geriatric conditions lacking effective treatments, or products in urgent clinical need without an approved predicate.The Emergency Registration Procedures track is triggered during public health emergencies, running testing, QMS verification, and evaluation in parallel.
Statutory Review and Timelines
Administrative processes are governed starting with a 3-day window for the regulatory authority to forward accepted dossiers to the evaluation department. For Class II and Class III applications, initial technical evaluations take 60 and 90 days respectively, while evaluations after a material supplement take 60 days. Clinical trial evaluations take 60 days, or 40 days after a supplement. The NMPA must make its final administrative decision within 20 days after receiving the evaluation comments, and certificates must be delivered within 10 days of approval. When supplementary materials are required, they are issued via a single "one-off" notification, and the applicant must submit all additions in a single delivery within exactly 1 year, or face immediate application rejection. Timeline extensions are limited at half the original timeline, and the clock pauses during the time taken by the applicant to supplement materials, perform QMS rectifications, or during external expert consultations and active field inspections.
Lifecycle Management, Coding, and Post-Market Changes
Approved devices receive a structured registration number following a standardized arrangement tracking national jurisdiction, imported status, registration year, risk tier, and product classification codes. Initial certificates last five years. You must submit renewals exactly six months before they expire. Any major changes to design, raw materials, manufacturing, or use require a formal change registration. Non-substantial alterations, such as a name or residence change of the registrant or domestic agent, only require a change filing within 30 days of the occurrence.
Financial Compliance and Post-Market Enforcement
The financial standard for medical device and IVD registration requires full payment after an application is formally accepted; failure to pay within the specified time limit results in the application being deemed voluntarily withdrawn and immediately terminated. For manufacturing licensing maintenance, Class II and Class III manufacturers must submit a renewal application within a regulatory window of 30 to 90 working days prior to the license's expiration date, or the application will be rejected. If manufacturing conditions change to the point of non-conformance with the quality management system, production must be stopped immediately, and any Class I manufacturing site that fails its post-filing inspection will have its filing canceled entirely. Finally, if a distributed device is discovered to be defective or non-compliant, the manufacturer bears the immediate operational and financial burden of executing a mandatory recall to halt production, notify downstream entities, and physically destroy or recall the inventory.
Frequently Asked Questions (FAQs)
Under China Medical Device Regulations, what are the primary barriers to entry for an overseas company before NMPA even looks at the product?
You face two major barriers right at the start. First, you cannot apply directly from abroad; you must legally appoint an official domestic agent inside China to handle your submissions. Second, you must have a valid marketing certificate like an FDA clearance or CE mark from your home country or where your factory is located.
Are you completely stuck if your device does not have home-country approval for China Medical Device Registration?
Not always. If your product gets officially recognized under China’s special innovative product track, you can skip the home-market certificate requirement. Even if it is not classified as a medical device in your country, you are not exempt under China medical device regulations. You must show official proof that you can legally sell it there as a non-medical product.
What are the exact evaluation timelines for importing Class II and Class III products?
Class II reviews take up to 60 days, and Class III reviews take up to 90 days. If inspectors find issues and you submit the follow-up review takes up to 60 days for both classes.
Do Chinese inspectors from the National Medical Products Administration (NMPA) travel overseas to audit foreign factories ?
Yes, they can. During the technical review stage, the CMDE can trigger a system inspection. They will send the Center for Food and Drug Inspection (CFDI) to audit your facility to see if your design and production match GMP standards, focusing heavily on raw data verification if you used a self-test report.
What are the extra technical testing complications for Class III IVD reagents compared to standard devices?
Class III IVDs have much tougher rules. Your Product Technical Requirements (PTR) must include a mandatory annex breaking down your main raw materials and manufacturing steps. You also must provide clean test reports from three entirely separate batches, and you are forced to use Chinese national reference standards during testing if they exist for your reagent.
How long does an approved certificate last and what are the deadlines to keep it alive?
An approved certificate lasts five years. You must submit a renewal exactly six months before it expires. For Class II or III manufacturing licenses, you must apply 30 to 90 working days before expiration, or the application will be rejected.
Japan Medical Device Registration
Navigating the healthcare market in Japan requires a comprehensive understanding of local law, where overseas manufacturers must comply with the Japan medical device regulations set forth under the PMD Act. The regulatory landscape is split between the Ministry of Health, Labour and Welfare (MHLW), which handles final product approvals and administrative guidance, and the Pharmaceuticals and Medical Devices Agency (PMDA), which focuses on technical areas like reviews and post-market safety.If you are a foreign manufacturer, you cannot just handle your own Japan medical device registration or sell devices directly. You are legally required to appoint a local representative in Japan, which must be a licensed Japanese Marketing Authorization Holder (MAH). This local MAH takes on all legal responsibility for compiling your evidence and ensuring device safety and efficacy before any application is turned in. You must keep this position filled; if there is a vacancy post-approval and you do not find a replacement, the authorities can completely revoke your marketing approval. Additionally, if your representative changes their name or address, you must formally notify the Ministry or your Registered Certification Body (RCB) within 30 days.
Device Classification and Japan Medical Device Registration Pathways
Japan splits medical devices into four risk classifications, ranging from Class I (extremely low risk) to Class IV (high risk). An important detail under Japan medical device regulations is that Software as a Medical Device (SaMD) is legally treated exactly like physical hardware. Depending on where your device lands in these classes you have to follow one of three pathways through your MAH. For Class I extremely low-risk devices your MAH just submits a basic notification to the PMDA. For the Certification Pathway under Article 23-6 Paragraph 1 if your Class II or Class III device matches specific performance standards set by the MHLW you go through a third-party certification body registered with the government to get a Certification of Conformity. For the Approval Pathway covering Class II or III without standards and all Class IV items you must get formal Marketing Approval from the MHLW. For highly novel items with completely new structures the MHLW has to consult the Pharmaceutical Affairs and Food Sanitation Council before letting you into the market.
Dossier Requirements and Technical Reviews Under Japan Medical Device Regulations
When building your application dossier for the MHLW or an RCB you have to include complete data packages covering clinical studies, physical structures, directions for use, and side effects based on strict domestic rules regardless of what the US FDA or a European Notified Body already reviewed. You also need to attach structural layouts or floor plans of your manufacturing plants to prove they meet clean-room and sterilization standards. There is an optimization rule though if your device uses ingredients or components already registered in the local Drug Master File you can legally swap out some of the required data with official registration certificates. For the Approval Pathway the PMDA reviews things on a case-by-case basis instead of using generalized rules. To figure out your exact testing and document requirements you have to book formal fee-based face-to-face consultation meetings with the PMDA. If you are selling SaMD the PMDA evaluates it against specific Review Points pooled from approved software since 2014 which covers distinct categories like peritoneal dialysis software, dental implant tools, ophthalmic surgery planners, endoscopic lesion detectors, and computer-aided diagnosis programs for image interpretation.
QMS Audits, Facility Registration, and Fast-Track Pathways
Every overseas plant that handles key steps like design, assembly, sterilization, or packaging has to get a Foreign Manufacturer Registration from the MHLW by submitting its location and corporate details. On top of that your facilities must pass QMS audits via document checks or on-site visits. These audits happen when you first apply and then repeat periodically every subsequent period of not less than three years. There is an exemption rule where you can skip the pre-market QMS audit for a new item if you already hold a valid Certificate of Conformity for a device in the same technical group made at that exact same physical facility. If you have a high-need or emergency item there are fast tracks available where the MHLW can prioritize the reviews and QMS audits for designated Orphan Medical Devices or products meeting urgent medical needs. There is also a Special Emergency Approval Track that bypasses standard lines if your device is urgently required to stop a severe health hazard as long as it is already fully authorized for sale in a foreign country that the government recognizes as having equivalent safety and quality standards.
Post-Market Vigilance, Labeling, and Penalties Under Japan Medical Device Regulations
Once your device is on the market you have to follow carefully monitoring rules through your representative which includes mandatory usage Assessment Surveys for certain devices where you must file a formal report within three months after the investigation window. If your device is suspected of causing disease, disability, death, or spreading an infection you have to report it immediately to the MHLW or PMDA. The same immediate reporting applies if you start a voluntary product recall. If you manufacture life-supporting or permanently implanted Designated Medical Devices you are legally required to keep permanent records of every patient's name and address for tracking during a crisis. Before clearing customs or going on display the device or its packaging must be labeled with your local MAH's name and address, the product name, lot number, net contents, and any parameters forced by Article 41(3) or 42(2) standards. If you break the rules authorities can suspend your product lines or order immediate field recalls. Under the dual-liability rules in Article 90 major infractions like selling unapproved items or ignoring recall orders can bring individual jail time and a corporate fine of up to 100 million yen. Defying an inspector or lying on application data carries an individual fine of up to 500,000 yen.
Costs and Maintenance Timelines
Foreign manufacturers have to pay non-refundable fees for applications, renewals, and audits based on the actual physical cost of the review and PMDA fees go directly into their corporate revenue. For factory accreditation a new On-site exam costs a 90,000 JPY government fee and a 143,900 JPY PMDA fee which is 233,900 JPY total while a Document-based exam costs 90,000 JPY to the government and 62,600 JPY to the PMDA making it 152,600 JPY total. To renew an On-site review is 23,400 JPY government and 69,700 JPY PMDA for a 93,100 JPY total while a Document renewal drops to 23,400 JPY government and 42,900 JPY PMDA for a 66,300 JPY total. Adding a category requires a 90,000 JPY government fee plus the matching PMDA fee and changing a category costs the exact same as a renewal. Getting your physical Accreditation Certificate issued or reissued costs a flat government fee of 19,700 JPY. These registrations do not last forever where plant registrations, QMS conformity certificates, and product certifications expire after a period specified by Cabinet Order of not less than three years and must be renewed. The commercial licenses held by your local representative must be renewed every six years. Any records you keep regarding product transfers or clinical trials must be safely archived for a timeline of exactly two years. Finally if a certified device is not manufactured or sold in the market for a consecutive window of three years without a good reason authorities have the right to cancel your approval entirely.
Frequently Asked Questions
Can my US FDA clearance or CE mark help to speed up the Japan medical device registration process or lower costs?
No, it does not help you get a fast track or any discounts. You still have to pass the same local guidelines and basic standards like everyone else under Japan medical device regulations. The only exception is if you use the emergency track for an urgent health crisis, where having a foreign approval in an approved country is a prerequisite.
What are the exact fees to pay for the factory accreditation and renewals?
For a new application it costs a total of 233,900 JPY if they do an on-site exam . If it is only document-based then it costs 152,600 JPY . for renewals it costs 93,100 JPY for on-site and 66,300 JPY for documents . Also there is a flat fee of 19,700 JPY to get the actual certificate paper issued.
Do quality audits and factory registrations last forever under Japan medical device regulations?
No, they expire. Your plant registration and quality certificates only last for a time set by order (which cannot be less than three years), so you must keep renewing them to maintain your Japan medical device registration. The local representative's license also has to be renewed every six years.
will they come to do a physical audit at our factory or can we just send documents?
The system allows both ways so you can have an on-site track or a document track for your applications and changes . Doing the audit on-site always costs more money than just sending documents . But the minister can still order an on-site visit anyway if your device needs it.
Do we have to show clinical study data to register in Japan?
Yes you must. When you send the application to the government or the certification body you have to attach full clinical study data along with how the device is made and its side effects . This has to follow the local rules even if an overseas body already checked it.
Is there a checklist we can download to check our device standards?
Yes if you are doing the third-party certification you have to download and fill out the specific conformity checklist for your device type . These checklists come under notification 112 of 2005 and you have to use the right one depending on your device dates to show you meet the basic standards under article 41 paragraph 3.
South Korea Medical Device Registration
The medical device market in South Korea requires understanding their four classification systems which goes from the Medical Device Act to implementing regulations, and about 35 active MFDS notifications. Under South Korea medical device regulations, devices and In Vitro Diagnostics (IVDs) fall into four risk categories ranging from Class I (very low risk) to Class IV (high risk). Class I is very low risk and just needs a product notification with NIDS. Class II low risk devices usually take a 5 day NIDS certification route which is split into substantial equivalent devices that are identical to a predicate in things like intended use and raw materials, and modified devices that have the same use but differ in testing or instructions. But Class II has to bypass NIDS and go straight to the MFDS for formal approval if they need clinical test reports, digital healthcare like telemedicine, undefined nomenclature, or are combination products with drugs. All high risk Class III and Class IV products plus any totally new novel devices without a predicate need direct approval from NIFDS. A standard technical document review takes 55 days but goes up to 70 days for a safety and efficacy review if clinical data is required. Clinical trial reports are waived under general reviews for substantially equivalent items but are mandatory under an SER if differences in use, mechanism, or raw materials alter the safety profile. For cutting edge tech the MFDS might use an external review pool of over 300 experts. Once in the market high risk items face intensive tracking where the MFDS monitors 52 specific items that could cause fatal harm. This includes 48 implantable items used over a year and 4 life sustaining devices used outside hospitals, requiring strict records from both importers and doctors.
Digital Medical Products Act Under South Korea Medical Device Regulations
These transitional rules where digital medical devices previously authorized under the standard MDA are legally recognized under this Act. Importers can register low risk devices by product group while moderate to high risk profiles need individual product licensing. Submission dossiers must include technical data, QMS data, and clinical study records. If a digital medical device contains integrated components performance certification data has to be put directly into the submission dossier. Network subscribed or cloud based software as a medical device is exempt from standard distribution business notifications but must still fulfill core software compliance submissions. Administrative reviews for an initial business permission take 25 days while modifications take 15 days. Under an automatic approval. If the MFDS fails to notify the applicant or issue an extension within these windows the permission is legally deemed granted on the following day. Companies marketing digital convergence drugs which combine a drug or biologic with digital software or a device must get a specific permission by item. This requires data packages for both parts alongside registering the overseas factory name, location, and quality control parameters. Mandatory regulatory fees apply to permissions, certifications, and modifications and are paid directly to designated third party agencies if they handle these functions for the MFDS.
The Act on In Vitro Diagnostic Medical Devices for South Korea Medical Device Registration
The Act on In Vitro Diagnostic Medical Devices functions as a specialized extension of general medical device law, meaning the primary Medical Device Act (MDA) still applies to all imported IVD reagents, equipment, and software unless explicitly stated otherwise. To secure an IVD-specific South Korea medical device registration, low-risk IVD items can be registered by item category, while standard or higher-risk products require separate registration for each individual item. Dossiers must feature manufacturing facility QMS records, technical documents, and clinical performance data.
For companion diagnostic (CDx) medical devices used to determine patient suitability for a specific drug, the law permits a concurrent review. If the MFDS reviews the drug and the CDx at the same time, the paperwork submitted for the drug under the Pharmaceutical Affairs Act can satisfy the CDx technical submission requirements for your South Korea medical device registration.
The MFDS has to notify applicants of an import business permission decision within 25 days, or 15 days for a significant modification affecting safety or effectiveness. Both timelines have an automatic approval clause the day after the deadline expires if the ministry fails to give a decision or a formal extension. While flat-rate fees are not itemized, the MFDS can make importing entities pay all operational expenses for product performance evaluations. Final goods must have localized labels explicitly stating In Vitro Diagnostic Medical Device, and package inserts can be delivered digitally via USB, CD, or authorized websites.
Domestic Business Licensing and Infrastructure Requirements
An overseas manufacturer cannot sell directly into South Korea without setting up localized infrastructure or using a licensed local importer. The importing entity must get an Import Business License from the specific regional office of the MFDS where their physical site is located. This process uses a standalone business license that cannot be held without an active product file, so the applicant must have at least one product license and both reviews are done at the same time. The formal review for an import business license takes 25 days and is issued only when the product license gets final approval. Prior to submitting applications the importer must establish physical facilities and quality management systems for doing quality inspections. But an exception allows testing to be officially entrusted to an authorized third party laboratory under Prime Ministerial Decree, bypassing certain localized facility requirements. Also the importer must designate a qualified local Quality Manager. Finally the applicant must provide mandatory medical certificates from a medical specialist proving they are not a mental patient, are adequate to be an importer, and are not addicted to drugs or other toxic substances.
Frequently Asked Questions
Under South Korea Medical Device Regulations, what are the primary structural barriers to entry for an overseas manufacturer trying to sell directly?
Overseas manufacturers cannot sell directly into the market. You must partner with a local importer who maintains a physical setup, quality management systems, and an active business license from the regional MFDS office. Also, standalone business licenses are not allowed; because the importer must file a product license at the same time, you cannot secure a business license without an active product file.
Are there personal background or health requirements that act as legal disqualifiers for establishing an import bridge?
Yes, the local importing applicant or managing officers face strict disqualifications if they have adult guardianship, bankruptcy, or criminal histories . They also have to submit medical certificates from a doctor proving they are not mental patients, are fit to be an importer, and are not addicted to drugs or toxic substances.
Is there an automatic approval mechanism if the ministry delays its decision during South Korea Medical Device Registration?
Yes, but only under the Digital Medical Products Act and the Act on In Vitro Diagnostic Medical Devices. If the MFDS does not notify you about a business permission or issue an extension within the 25 days for initial apps or 15 days for modifications, the permission is legally deemed granted on the very next day.
When is an overseas manufacturer required to submit a clinical trial report, and when can it be waived?
A clinical trial report is needed for a safety and efficacy review if your device has differences in intended use, mechanism of action, or raw materials that could change safety and efficacy . for class II devices clinical reports force you to go directly to MFDS or NIFDS for approval . clinical data is completely waived under a general technical document review if the device is proven to be substantially equivalent to an existing legally marketed device in korea.
How does the regulatory framework handle the costs and fees for entry, and can external agencies collect them?
Mandatory fees apply for getting or changing permissions, certifications, notifications, or requesting preliminary technical reviews . The exact cash amounts are not listed because they are set by prime ministerial or presidential decrees . if these functions are done by a designated third party agency or entrusted institution you pay the fees directly to them based on MFDS standards . For ivd products the minister can make the importer pay all operational expenses for performance evaluations.
Are there provisions for bypassing localized quality testing facilities through third-party audits or laboratory delegations?
Yes, while importers normally need local physical facilities and quality systems to inspect arriving goods, an exception is allowed under prime ministerial decree . quality testing can be officially entrusted to an authorized third party laboratory, letting you bypass some local facility rules.
Does south korea require the registration of the actual overseas manufacturing site or factory?
Yes specifically if you register a digital convergence drug which combines a drug or biological product with digital software or a device. The importer has to register the exact name, physical location, and quality control parameters of the overseas factory with MFDS, and also register any changes to the facility later on.